Skip to main content
SpringerLink
Log in

Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin

  • Published:
Folia Microbiologica Aims and scope Submit manuscript

Abstract

Due to high resistance, standard chemotherapy of biofilm-associated staphylococcal infections is ineffective and a number of alternative approaches to antimicrobial treatment have been proposed. Minimum inhibitory concentration (MIC) and biofilm inhibitory concentration (BIC) of oxacillin (Oxa), vancomycin (Van), linezolid (Lzd) and lysostaphin (Lss) as well as the possible synergistic effect of the antibiotics and lysostaphin were determined. The Lss susceptibility ofStaphylococcus aureus planktonic and biofilm cultures varied and was strain-dependent. The synergistic effect of sub-BICLss+Oxa was observed for methicillin-sensitiveS. aureus (Ms Sa) and methicillin-resistantS. aureus (Mr Sa), but not for heterogeneously vancomycin-resistantS. aureus (Vh Sa) biofilm. Van with sub-BICLss was effective against Ms Sa and Mr Sa biofilm, when applied in three subsequent doses. Only sub-BICLss+Lzd combination, given as three cycles therapy, was effective in disruption of all 3 (Ms Sa, Mr Sa, Vh Sa) biofilms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BIC:

biofilm inhibitory concentration

Mr Sa :

methicillin-resistantS. aureus

FITC:

fluorescein isothiocyanate

MTT:

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

Vh Sa :

S. aureus heterogeneously resistant to vancomycin

Lss:

lysostaphin

MIC:

minimal inhibitory concentration

Ms Sa :

methicillin-sensitiveS. aureus

Lzd:

linezolid

Oxa:

oxacillin

Van:

vancomycin

References

  • Barequet I.S., Ben Simon G.J., Safrin M., Ohman D.E., Kessler E.:Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis.Antimicrob.Agents Chemother. 48, 1681–1687 (2004).

    Article  PubMed  Google Scholar 

  • Boyle-Vavra S., Carey R.B., Daum R.S.: Development of vancomycin and lysostaphin resistance in a methicillin-resistantStaphylococcus aureus isolate.J.Antimicrob.Chemother. 48, 617–625 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Černohorská L., Votava M.: Determination of minimal regrowth concentration (MRC) in clinical isolates of various biofilm-forming bacteria.Folia Microbiol. 49, 75–78 (2004).

    Article  Google Scholar 

  • Climo M.W., Ehlert K., Archer G.L.: Mechanism and suppression of lysostaphin resistance in oxacillin-resistantStaphylococcus aureus.Antimicrob.Agents Chemother. 45, 1431–1437 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Dajcs J.J., Thibodeaux B.A., Girgis D.O., Shaffer M.D., Delvisco S.M., O’Callaghan R.J.: Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit.Invest.Ophthalmol.Visual Sci. 43, 3712–3716 (2002).

    Google Scholar 

  • Drago L., Vecchi E.D., Valli M., Nicola L., Gismondo M.R.: Effect of linezolid in comparison with that of vancomycin on glycocalyx production:in vitro study.Antimicrob.Agents Chemother. 46, 598–599 (2002).

    Article  PubMed  CAS  Google Scholar 

  • El-Azizi M., Rao S., Kanchanapoom T., Khardori N.:In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci.Ann.Clin.Microbiol.Antimicrob. 4, 1–9 (2005).

    Article  Google Scholar 

  • Fux C.A., Stoodley P., Hall-Stoodley L., Costerton J.W.: Bacterial biofilms: a diagnostic and therapeutic challenge.Expert Rev. Anti-infect.Ther. 1, 667–683 (2003).

    Article  PubMed  Google Scholar 

  • Gander S., Hayward K., Finch R.: An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing anin vitro pharmacokinetic model.J.Antimicrob.Chemother. 49, 301–308 (2002).

    Article  PubMed  Google Scholar 

  • Goetz F.:Staphylococcus and biofilms.Mol.Microbiol. 43, 1367–1378 (2002).

    Article  Google Scholar 

  • Hall-Stoodley L., Costerton J.W., Stoodley P.: Bacterial biofilms: from the natural environment to infectious diseases.Nature Rev. 2, 95–106 (2004).

    Article  Google Scholar 

  • Kairo S.K., Bedwell J., Tyler P.C., Carter A., Corbel M.J.: Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines.Vaccine 17, 2423–2428 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Kiri N., Archer G., Climo M.W.: Combinations of lysostaphin with β-lactams are synergistic against oxacillin-resistantStaphylococcus epidermidis.Antimicrob.Agents Chemother. 46, 2017–2020 (2002).

    Article  PubMed  Google Scholar 

  • Lewis K.: Riddle of biofilm resistance.Antimicrob.Agents Chemother. 45, 999–1007 (2001).

    Article  PubMed  CAS  Google Scholar 

  • National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically.Approved Standard 5th ed. M7-A5, 1–54 (2000).

  • Pitts B., Hamilton M.A., Zelver N., Stewart P.S.: A microtiter-plate screening method for biofilm disinfection and removalJ.Microbiol.Meth. 54, 269–276 (2003).

    Article  Google Scholar 

  • Prakash B., Veeregowda B.M., Krishnappa G.: Biofilms: a survival strategy of bacteria.Curr.Sci. 85, 1299–1307 (2003).

    Google Scholar 

  • Růžička F., Hola V., Votava M., Tejkalová R., Horvát R., Heroldova M., Woznicova V.: Biofilm detection and the clinical significance ofStaphylococcus epidermidis isolates.Folia Microbiol. 49, 75–78 (2004).

    Article  Google Scholar 

  • Walencka E., Sadowska B., Różalska S., Hryniewicz W., Różalska B.: Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication.Polish J.Microbiol. 54, 191–200 (2005).

    Google Scholar 

  • Wilcox H.M.: Efficacy of linezolidversus comparator therapies in Gram-positive infections.J.Antimicrob.Ther. 51 (Suppl. S2), ii27-ii35 (2003).

    Google Scholar 

  • Wu J.A., Kusuma C., Mond J.J., Kokai-Kun J.F.: Lysostaphin disruptsStaphylococcus aureus andStaphylococcus epidermidis biofilms on artificial surfaces.Antimicrob.Agents Chemother. 47, 3407–3414 (2003).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology and Infectious Biology, Institute of Microbiology and Immunology, University of Łódż, Poland

    E. Walencka, B. Sadowska & B. Róžalska

  2. Department of Industrial Microbiology and Biotechnology, Institute of Microbiology and Immunology, University of Łódż, Poland

    S. Róžalska

  3. National Institute of Public Health, Warsaw, Poland

    W. Hryniewicz

Authors
  1. E. Walencka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Sadowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Róžalska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Hryniewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Róžalska
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This study was supported by the grant 2PO5A 149 29 from thePolish Scientific Research Committee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walencka, E., Sadowska, B., Róžalska, S. et al. Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin. Folia Microbiol 51, 381–386 (2006). https://doi.org/10.1007/BF02931580

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02931580

Keywords

Search

Navigation